Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184 · View on ClinicalTrials.gov ↗
Study Summary
IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.
Conditions Studied
Interventions
- DRUG IMGN151
Study Locations (20)
California
- City of Hope National Medical Center /ID# 269036 — Duarte
- Moores Cancer Center /ID# 269040 — La Jolla
- University of California Los Angeles Medical Center /ID# 269037 — Los Angeles
- Hoag Memorial Hospital Presbyterian /ID# 269047 — Newport Beach
Florida
- AdventHealth Celebration /ID# 269030 — Kissimmee
- Mount Sinai Medical Center /ID# 269050 — Miami
- Miami Cancer Institute at Baptist Health /ID# 269041 — Miami
- Florida Cancer Specialists- Sarasota Cattlemen /ID# 269055 — Sarasota
New York
- Roswell Park Cancer Institute /ID# 269043 — Buffalo
- Long Island Jewish Medical Center /ID# 269035 — New Hyde Park
- Columbia University Irving Medical Center /ID# 269033 — New York
Massachusetts
- Massachusetts General Hospital /ID# 278119 — Boston
- Dana-Farber Cancer Institute /ID# 269039 — Boston
Alabama
- University of Alabama at Birmingham /ID# 269045 — Birmingham
Colorado
- UCHSC Anschultz Cancer Pavilion /ID# 269056 — Aurora
Illinois
- University of Chicago Medical Center /ID# 269028 — Chicago
Michigan
- Karmanos Cancer Institute - Detroit /ID# 269052 — Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2023-01-11 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05527184
The ClinicalTrials.gov registry entry for NCT05527184 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 603 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention — of which IMGN151 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05527184 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Florida, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05527184 about?
NCT05527184 is a clinical study titled "First in Human Study of IMGN151 in Recurrent Gynaecological Cancers". IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; r...
What is the current status of trial NCT05527184?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 256 participants. The study started on 2023-01-11. Estimated completion is 2027-02.
What conditions does trial NCT05527184 study?
This clinical trial studies the following conditions: Endometrial Cancer, Cervical Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma of Ovary. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05527184?
The interventions under investigation include: IMGN151 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05527184?
This trial is sponsored by AbbVie, which has 603 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05527184 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.